Our Impact

See the difference your support makes for children with neuroblastoma worldwide.

Clinical Trials Funded
0
Countries Connected
0 +
People Reached for Neuroblastoma Day 2025
0 M+
Families Connected to Experts & Support Each Year
0 +

Where Your Support Goes

Research & Awareness:

Funding cutting-edge neuroblastoma research, hosting expert-led webinar sessions, and driving early detection awareness worldwide through International Neuroblastoma Awareness Day.

Family & Community:

Connecting families navigating neuroblastoma with resources, peer support, and a global community of advocates who understand what they’re going through.

Grassroots Action:

Empowering ambassadors and volunteers around the world to raise awareness in their communities, from lemonade stands to local advocacy campaigns.

Shir for Life Timeline
Milestone 1

Funding Research That Matters

With strategic, targeted funding, Shir for Life has supported three clinical trials across the United States and Israel, including precision immunotherapy research at Children's Hospital of Philadelphia and a multi-year collaboration with the Israel Cancer Research Fund, amplified through matching grants.

Milestone 2

International Neuroblastoma Awareness Day

Founded by Shir for Life in 2024, Neuroblastoma Day on December 5 unites families, clinicians, hospitals, researchers, and partner organizations across more than 50 countries, reaching over 1.3 million people worldwide and growing each year. The Global Neuroblastoma Pledge has drawn voices from 69 locations worldwide, from Osaka to Oregon.

Milestone 3

Bridging Families and Experts Worldwide

Through a monthly global webinar series, Shir for Life has built something rare in the childhood cancer space: a direct, ongoing connection between the world's foremost neuroblastoma researchers and the families navigating this disease. More than 20 leading clinicians and scientists from 12+ institutions across 7 countries, including Memorial Sloan Kettering, Children's Hospital of Philadelphia, St. Jude Children's Research Hospital, Institut Curie in Paris, Great Ormond Street Hospital in London, Dana-Farber, Bambino Gesù in Rome, and Hospital for Sick Children in Toronto, present alongside parents, answering questions and sharing the latest advances in real time. The series has featured the presidents of all three major global research consortia, COG, SIOPEN, and NANT, and is complemented by an annual Parents Conference with 100+ attendees and the Neuroblastoma Nurses Conference in Israel with approximately 70 nurses.

Milestone 4

Supporting Families Directly

Shir for Life doesn't just connect families to information. The team personally consults with over 150 parents each year, helping them navigate diagnosis, understand treatment options, access clinical trials, and find the support they need. For many families around the world, this is their first connection to the global neuroblastoma community.In January, 2026, SFL Executive Director Einat Baralia was nominated to be the co-chair of the SIOPEN Advocate Committee.

Milestone 5

Advocating for Access

Shir for Life successfully advocated for IWILFIN, a critical maintenance therapy for high-risk neuroblastoma, to be included in Israel's national health basket in 2026, ensuring Israeli children can access this treatment through the public healthcare system.

Milestone 6

A Worldwide Partner Network

Collaborating with 20+ partner organizations across 12+ countries, alongside hospitals in the United States, United Kingdom, Greece, Israel, Switzerland, and France, and pharmaceutical and medical companies supporting awareness and education.

In their words

Some of the individual voices driving our mission and work.

“The Shir for Life Foundation provided critical funding to create and optimize a new precision immunotherapy which will catalyze our ability to test this new drug in children with high-risk neuroblastoma. We think that this new therapy has the potential to be a game changer and be applicable to most if not all children with neuroblastoma as a safe and effective treatment.” 

Dr. Yaël Mossé, Children’s Hospital of Philadelphia

dr

“We have developed a new model of neuroblastoma for pre-clinical studies, which better mimic the biological nature of the disease. Using this model, we have already uncovered several mechanisms which can explain disease progression. Our aim is to further study these mechanisms in order to offer new and better treatments for this deadly disease.” 

Dr. Chen Buxbaum, Rambam Medical Center

Dr. Chen Buxbaum

Be Part of the Impact

Whether you host a lemonade stand, join our ambassador community, or simply share our mission, every action moves us closer to a future without neuroblastoma.

Email Signup
Subscribe to our mailing list